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Bile acids are well-recognized stimuli of glucagon-like peptide-1 (GLP-1) secretion. This action has
beenattributed toactivationof theGprotein–coupledbileacid receptorGPBAR1 (TGR5), although
other potential bile acid sensors include the nuclear farnesoid receptor and the apical sodium-
coupled bile acid transporter ASBT. The aim of this study was to identify pathways important for
GLP-1 release and to determinewhether bile acids target their receptors onGLP-1–secreting L-cells
from the apical or basolateral compartment. Using transgenic mice expressing fluorescent sensors
specifically in L-cells, we observed that taurodeoxycholate (TDCA) and taurolithocholate (TLCA)
increased intracellular cAMP and Ca2. In primary intestinal cultures, TDCA was a more potent
GLP-1 secretagogue than taurocholate (TCA) and TLCA, correlatingwith a stronger Ca2 response
to TDCA.Using small-volumeUssing chambers optimized formeasuringGLP-1 secretion,we found
that both a GPBAR1 agonist and TDCA stimulated GLP-1 release better when applied from the
basolateral than from the luminal direction and that luminal TDCAwas ineffectivewhen intestinal
tissue was pretreated with an ASBT inhibitor. ASBT inhibition had no significant effect in nonpo-
larized primary cultures. Studies in the perfused rat gut confirmed that vascularly administered
TDCA was more effective than luminal TDCA. Intestinal primary cultures and Ussing chamber–
mounted tissues from GPBAR1-knockout mice did not secrete GLP-1 in response to either TLCA or
TDCA. We conclude that the action of bile acids on GLP-1 secretion is predominantly mediated by
GPBAR1 located on the basolateral L-cell membrane, suggesting that stimulation of gut hormone
secretion may include postabsorptive mechanisms. (Endocrinology 156: 3961–3970, 2015)
Gut hormones play key roles in the control of nutrientmetabolism and are relevant for the treatment of type
2 diabetes and obesity (1). In particular, glucagon-like
peptide-1 (GLP-1) promotes insulin release and lowers
glucagon secretion from the pancreas and also inhibits
food intake and gastrointestinal motility (2). GLP-1 is re-
leased from enteroendocrine L-cells, which comprise upto
1%of intestinal epithelial cells. They are scattered along
the intestinal tract, increasing in density toward the distal
small intestine and colon. These open-type cells make di-
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rect contactwith thegut lumenandcan sensenutrients and
other components within the gastrointestinal tract. L-cell
sensory mechanisms include G protein–coupled recep-
tors, nutrient transporters, and ion channels (3).
The properties of GLP-1 have been exploited for the
treatment of type 2 diabetes via the use of GLP-1mimetics
and inhibitors of GLP-1 inactivation by dipeptidyl pepti-
dase-4 (4). The glucose dependence of GLP-1–triggered
insulin release results in a low incidence of hypoglycemic
side effects with these treatments, and GLP-1 mimetics
offer the additional benefit of promoting weight loss. Un-
derstanding the mechanisms underlying the release of en-
dogenous GLP-1 may facilitate the development of novel
therapeutic approaches that promote secretion of endog-
enous gut hormones, in theory providing enhanced effects
compared to those of exogenous agonists while possibly
avoiding side effects due to the natural site of release and
action of the endogenous hormone. This theory is sup-
ported by the results of bariatric procedures such asRoux-
en-Y gastric bypass (RYGB). After RYGB, glycemic con-
trol often improves within days and precedes significant
weight loss (5). Alterations in gut hormone signaling, in-
cluding 10-fold elevations of GLP-1 and peptide YY
concentrations, probably contribute to the observed im-
provement in insulin secretion and decreased appetite (6).
Bile acids are amphipathic, steroid-based molecules
that aid the digestion of fat when released into the upper
small intestine. Ninety-five percent of bile acids are reab-
sorbed in the lower small intestine by the apical sodium-
dependent bile acid transporter (ASBT). Bile acids are de-
tected by the nuclear farnesoid X receptor (FXR) (7) and
the G protein–coupled bile acid receptor GPBAR1
(TGR5), a primarily Gs-coupled receptor that increases
intracellular cAMP levels upon activation (8). In L-cells,
GPBAR1 activation resulted in GLP-1 release. The recep-
tor has also been reported to activate type 2 iodothyronine
deiodinase and promote energy expenditure in other tis-
sues (9). Plasma bile acid concentrations have been re-
ported to increase after RYGB and have been hypothe-
sized to contribute to the beneficial metabolic effects of
surgery (10), although this does not explain the early post-
operative improvements (11).
Numerous groups are attempting to design effective
drugs to target GPBAR1 and thereby to stimulate endog-
enous GLP-1 release as a new treatment for diabetes. GP-
BAR1 agonists have been shown to increase GLP-1 secre-
tion and lower blood glucose in animalmodels (9, 12), but
toxic side effects on the gallbladder have been reported
(13). It has therefore been suggested that nonabsorbable
agents or agonists with very low systemic exposure might
be capable of activating L-cells without causing toxic sys-
temic levels (14), although this approach depends on a
better understanding of how bile acids and GPBAR1 li-
gands access their receptors.
In this article, we investigated the actions of bile acids
on primary L-cells and intact intestinal epithelium. Single-
cell imaging revealed that bile acids elevate cAMP and
Ca2 in L-cells. We established a Ussing chamber system
to measure GLP-1 release and showed that in both this
model and the perfused intestine bile acids preferentially
stimulate GLP-1 secretion when applied from the baso-
lateral (vascular) direction. In the Ussing chamber setup,
apically applied taurodeoxycholate (TDCA) was largely
ineffective when administered after pretreatment with an
inhibitor of the ASBT, and both TDCA and a GPBAR1
agonist were more effective when applied to the basolat-
eral than to the apical surface. GLP-1 secretory responses
to bile acids and the GPBAR1 agonist were abolished in
tissues fromGPBAR1-knockoutmice.Our combineddata
suggest that bile acids target basolaterally located GP-
BAR1 on L-cells and that luminally applied GPBAR1 li-
gands are effective only after absorption across the epi-
thelial layer.
Materials and Methods
Transgenic mice
All animal procedures were approved by local ethical review
committees and conformed to relevant national guidelines.
GLU-Venus mice were described previously (15). GCaMP3 was
expressed in L-cells by crossing GLU-Cre (16) with ROSA26-
tdRFP (17) and ROSA25-GCaMP3 (18) strains. The cAMP sen-
sor Epac2camps (19, 20) was expressed in L-cells under prog-
lucagon promoter control inGLU-Epac transgenicmice (21). All
mice were backcrossed onto a C57B6 genetic background, and
both sexes were used in approximately equal numbers. GP-
BAR1-knockout mice were described previously (9). These were
imported from Lausanne to Cambridge for this study, and only
males were used for this part of the study.
Primary murine intestinal cultures
Cultures were prepared as described previously from 2- to
5-month-old mice (15). Lower small intestinal cultures con-
tained12 cm of tissue proximal to the ileocolic junction, with
the exception of experiments involving GPBAR-knockout
mouse tissue, forwhich regions up to 2 cm and between 7 and 15
cm proximal to the ileocolic junction were used. Tissue was di-
gested with 0.3 to 0.4 mg/mL collagenase XI, centrifuged at
100 g, and resuspended in DMEM (25 mmol/L glucose) sup-
plemented with 10% (vol/vol) fetal bovine serum, 2 mmol/L
L-glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.
Aliquots of tissue digests were plated and incubated at 37°C and
5% CO2.
Primary murine intestinal single-cell suspension for
fluorescence-activated cell sorting (FACS)
Tissue was digested in 1 mg/mL collagenase XI in calcium-
free Hanks’ buffered salt solution, centrifuged at 300  g, re-
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suspended in a low chloride (Cl) buffer (40 mmol/L sodium
citrate, 75mmol/L sodium acetate, 3.5 mmol/L KCl, 10mmol/L
HEPES, 4mmol/L sodium hydrogen carbonate, and 5.5mmol/L
glucose [pH7.4]), with 1% (wt/vol) fatty acid–free bovine serum
albumin (BSA). Single cell suspensions were separated by flow
cytometry using a MoFlo Beckman Coulter Cytomation sorter
(Coulter Corp). Side scatter, forward scatter, and pulse-width
gates excluded debris and aggregates. Venus-positive cells were
collected alongside negative (control) cells (15) into lysis buffer
for mRNA extraction.
RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNA from FACS-isolated cells and whole tissue seg-
ments was isolated using a micro scale RNA isolation kit
(RNeasy; Qiagen) and TRI Reagent, respectively. Next, 200 to
350 ng of RNA was reverse-transcribed according to standard
protocols using a Peltier Thermal Cycler PTC-225 (MJ Re-
search). qRT-PCR was performed with a 7900 HT Fast Real-
TimePCR system (AppliedBiosystems). The PCRmix contained
a first-strand cDNAtemplate, primers (TaqMangene expression
assays; Applied Biosystems), and PCRMasterMix (Applied Bio-
systems). Expression was compared with that of -actin mea-
sured on the same sample in parallel, giving a cycle threshold
difference (CT) for-actinminus the test gene.Mean, SEM,and
statistics were obtained for the CT data and converted to rel-
ative expression levels (2CT) for presentation.
GLP-1 secretion assay
Secretion studies were performed20 hours after plating on
24-well culture plates coated with Matrigel (BD Biosciences).
Cultures were incubated with test reagents in a standard saline
solution (see below) containing 0.1% (wt/vol) fatty acid–free
BSA, 10 mmol/L glucose and protease inhibitors (10 mol/L
amastatinhydrochloride, 100mol/LdiprotinA,and18mol/L
aprotinin) for 2 hours at 37°C. Media were collected and cen-
trifuged. Plated cells were mechanically disrupted in lysis buffer
containing 50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1% IGE-
PAL CA-630, 0.5% deoxycholic acid, and complete EDTA-free
protease inhibitor cocktail (Roche) to extract intracellular pep-
tides. GLP-1 was assayed in supernatants and cell extracts with
a total GLP-1 assay (MesoScale Discovery). GLP-1 secretion in
each well was expressed as a fraction of the total hormone mea-
sured in the same well.
Calcium imaging
Cultures were generated from GLU-Cre/ROSA26-tdRFP/
ROSA25-GCaMP3 mice (22). An inverted fluorescence micro-
scope (Olympus IX71) with a40 oil-immersion objective lens
was used for signal visualization. GCaMP3 and red fluorescent
protein (RFP) were excited at 488 nm and at 555 nm, respec-
tively, using a monochromator (Cairn Research) and a 75-W
xenon arc lamp, and GCaMP fluorescence was recorded using a
510-nm long-pass filter and an Orca ER camera (Hamamatsu).
Imageswere collected usingMetaFluor software (MolecularDe-
vices). Solutions were perfused at 1 mL/min. Mean fluores-
cence in the test agent was normalized to the mean basal fluo-
rescence of each cell, measured before the addition and after
washout of test compounds. Cells failing to exhibit a1.1-fold
change in GCaMP3 fluorescence to any stimuli, including the
positive control, were excluded from analysis.
cAMP imaging
Cultureswere generated fromGLU-Epacmice, expressing the
Förster resonance energy transfer–based sensor Epac2-camps
(19–21). An inverted fluorescence microscope with a 40 oil-
immersion objective lens was used for signal visualization. Ex-
citation at 435 nm was achieved using a 75-W xenon arc lamp
coupled to amonochromator controlled byMetaFluor software.
Cyan fluorescent protein (CFP) emission at 470 nm and yellow
fluorescent protein (YFP) emission at 535 nm were monitored
using anOptosplit II beam splitter (CairnResearch) and anOrca
ERdigital cameraandare expressedas theCFP/YFP fluorescence
ratio. Solutionswereperfusedat1mL/min.Datawere smooth-
ened with a sliding average across 30 seconds. Maximum ratios
were determined at baseline (30-second period before the test
condition) and after test reagent application. Responses to test
reagents are expressed relative to baseline levels.
Ussing chamber measurements
Mice were euthanized by cervical dislocation, and the whole
length of the intestine was transported in ice-cold L-15 medium.
The part of the ileum thatwas 2 to 7 cmproximal to the ileocecal
connection was removed and divided into 4 segments, each
1.25 cm long. Segments were cut longitudinally along the rem-
nants of the mesenteric attachment and washed with Ringer so-
lution containing 120mmol/LNaCl, 3mmol/LKCl, 0.5mmol/L
MgCl2, 1.25 mmol/L CaCl2, and 23 mmol/L NaHCO3, with 10
mmol/L mannitol. Serosa and most of the muscular layer were
stripped away with fine forceps. The segments were mounted in
an Ussing chamber (EM-LVSYS-4 systemwith P2400 chambers
and P2404 sliders; Physiologic Instruments). Up to 4 segments
from each animal were used. The active epithelial surface area of
each segment was 0.25 cm2. Both parts of the Ussing chambers
were filled with Ringer solution with added mannitol (10
mmol/L) apically and added glucose (10 mmol/L) basolaterally,
maintained at 37°C, and continuously bubbled with 5% CO2/
95% O2 (vol/vol). The transepithelial potential difference was
continuously monitored under open circuit conditions, using a
DVC 1000 amplifier (WPI) and recorded through Ag-AgCl elec-
trodes and 150 mmol/L NaCl agarose bridges. Recordings were
collected and stored using a Digidata 1440A acquisition system
and AxoScope 10.4 software (both from Molecular Devices).
First, transepithelial resistance and potential difference were al-
lowed to stabilize for 20 to 30minutes.During this period, trans-
epithelial resistance was assessed by measuring voltage changes
in response to 45-A pulses lasting 2.5 seconds, applied every
100 seconds. After stabilization of the electrical parameters, so-
lutions from both sides were removed. The apical sides of the
chambers were refilled with 1.2 mL of fresh Ringer solution
containing 10 mmol/L glucose, and the basolateral sides were
filledwith 1.2mLof freshRinger solution containing 10mmol/L
glucose, 0.1% fatty acid–free BSA, 10 mol/L amastatin, and
500 kIU/mL aprotinin. To prevent extensive foam formation,
Infacol (Forest Laboratories) was added to the basolateral com-
partment (1:105 dilution). At 5 to 10 minutes after the solution
exchange, samples (120 L) were taken from the basolateral
compartment and assayed for GLP-1 content as already de-
scribed. Drugs were then applied as stated, and GLP-1 concen-
trationsweremeasured typically 15, 60, and90minutes after the
addition of stimulants. Fresh solution was added to replenish
volumes lost by sampling.At the endof the experiment, forskolin
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(10 mol/L) and 3-isobutyl-1-methylxanthine (IBMX) (100
mol/L) were added bilaterally to test the viability and tightness
of the tissue. Preparations showing a 1 mV increase in the
transepithelial potential difference (2 of 87) were excluded from
further analysis. For each experimental protocol, numbers of
tissue sheets were equal to the numbers of animals used. Re-
ported GLP-1 secretion was normalized for 1 cm2 of the tissue
and a 60-minute secretion period.
Rat intestinal perfusion
Methods are described inmore detail elsewhere (23). In brief,
nonfasting male Wistar rats (250 g) were anesthetized with
fentanyl, fluanisone, and midazolam and placed on a 37°C
heated table. The upper half of the small intestine and the entire
large intestinewere removed after the supplying vasculaturewas
tied off. The remainder of the small intestinewas cannulated and
luminally perfusedwith isotonic saline at0.25mL/minat room
temperature. A catheter was placed in the cranial/superior mes-
enteric artery and perfused (7.5 mL/min) with modified Krebs-
Ringer buffer gassed with 95% O2 and 5% CO2 (vol/vol) and
warmed (37°C) by a Uniper UP-100 perfusion system (Hugo
Sachs; Harvard Apparatus). The venous effluent was collected
via a catheter in the hepatic portal vein. Once catheters were in
place, rats were killed by perforation of the diaphragm and the
systemwas allowed to equilibrate for 30minutes. Intestineswere
stimulated luminally or vascularly by adding agents to the rele-
vant perfusates. Luminal stimulations were applied at an initial
rate of 2.5 mL/min for the first 2 minutes to replace the saline
solution in the lumenand thereafter at 0.5mL/min. Lumenswere
then flushedwith a similar bolus of 0.9%NaCl (2.5mL/min) for
2 minutes, followed by infusion at 0.250 mL/min between stim-
ulations. Bombesin (BBS) (10 nmol/L vascularly)was included in
all experiments as a positive control. Venous effluent was col-
lected each minute, chilled on ice, and transferred to 20°C
within 30 minutes. Effluent GLP-1 concentrations were mea-
sured using a total GLP-1 RIA as described previously (24).
Chemicals
The standard saline solution contained 138 mmol/L NaCl,
4.5mmol/L KCl, 4.2mmol/LNaHCO3, 1.2mmol/LNaH2PO4,
2.6 mmol/L CaCl2, 1.2 mmol/LMgCl2, and 10mmol/L HEPES.
The low Na solution contained 138 mmol/L N-methyl-D-glu-
camine, 4.5 mmol/L KCl, 4.2 mmol/L NaHCO3, 1.2 mmol/L
NaH2PO4, 2.6 mmol/L CaCl2, 1.2 mmol/L MgCl2, and 10
mmol/L HEPES. Experiments involving a CoCl2 solution con-
tained143.4mmol/LNaCl, 4.5mmol/LKCl, 2.6mmol/LCaCl2,
1.2mmol/LMgCl2, and 10mmol/LHEPES, with or without the
addition of 5 mmol/L CoCl2. Rat perfusion buffer consisted of
Krebs-Ringer bicarbonate buffer supplemented with 0.1%BSA,
5% dextran T-70 (Pharmacosmos), 3.5 mmol/L glucose, 10
mol/L IBMX,and5mmol/Lpyruvate, fumarate, andglutamate
(pH 7.4).
Unless stated otherwise, all drugs and chemicals were ob-
tained from Sigma-Aldrich. Forskolin and IBMXwere dissolved
in dimethyl sulfoxide (DMSO). Taurolithocholic acid was dis-
solved inmethanol as a 100mmol/L stock. Taurocholic acid and
taurodeoxycholic acid stock solutions were 100 mmol/L, pre-
pared in saline solution. Stocks (1000 of the GPBAR1 agonist,
referred to as GPBAR-A [4-[[3,5 bis(trifluoromethyl)phenyl]
methyl]-6-(2-fluorophenyl)-4,5-dihydro-pyrido[3,2-f]-1,4-
oxazepin-3(2H)-one (25)] and GW4064 were prepared in
DMSO at 3 and 5 mmol/L, respectively. The ASBT inhibitor
(GSK2331583C) was obtained from GlaxoSmithKline and dis-
solved in DMSO (10 mmol/L). When DMSO was used as a sol-
vent, the working concentration never exceeded 0.2% (vol/vol).
Control studies confirmed that this concentration did not stim-
ulateGLP-1 secretion (data not shown). Stock solutions of amas-
tatin (10mmol/L) and aprotinin (20 500kIU/mL)were prepared
in water.
Statistical analysis
Comparisons between conditions were made using one- or
two-way ANOVAs and post hoc Bonferroni multiple compari-
sonor Student t tests as indicated in the figure legends (GraphPad
Prism), with a threshold for significance of P 	 .05.
Results
Bile acid–stimulated GLP-1 secretion from primary
intestinal cultures
In primary murine intestinal cultures, bile acids dose
dependently increased GLP-1 release (Figure 1). In both
ileal and colonic cultures, TDCA was more effective than
taurolithocholate (TLCA) or TCA, when compared at the
same concentration (100 mol/L). This order of potency
differs from the reported responsiveness of GPBAR1,
which prefers TLCA  TDCA  TCA (26). Consistent
with the idea that bile acids act through GPBAR1, a GP-
BAR1 agonist (GPBAR-A) (8, 25) was also effective in
stimulating GLP-1 secretion. The FXR agonist GW4064
(7) had little effect on GLP-1 release in intestinal cultures.
To ensure that the GLP-1 concentrations detected dur-
ing secretion studies were not due to the cytotoxic effects
of bile acids, a colorimetric lactate dehydrogenase assay
(Pierce) was used. Very low levels of lactate dehydroge-
nase were detected in the extracellular medium (0.1%–
0.5% total), and no correlation with the GLP-1 concen-
tration was observed (data not shown).
Bile acid–induced intracellular cAMP and calcium
changes
In considering the results of the secretion studies, it is
possible that bile acids trigger both GPBAR1-dependent
and -independent pathways in primary cultured L-cells.
We therefore performed single-cell imaging studies to
identify the intracellular signaling pathways activated by
bile acids in L-cells. For this, we used transgenic mice
which express fluorescent sensors for cAMP or Ca2 spe-
cifically in L-cells. These enable real-time monitoring of
these secondmessengers in response to a variety of stimuli.
First, we monitored cAMP changes using GLU-Epac
mice that express the Förster resonance energy transfer–
based cAMPsensorEpac2-camps inL-cells. Bile acids trig-
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gered robust elevation of cAMP (monitored as CFP/YFP)
in ileal L-cells, as predicted, based on the known recruit-
ment by GPBAR1 of Gs proteins and activation of ade-
nylate cyclase (Figure 2, A and B). TDCA (10 mol/L and
100 mol/L), TLCA (10 mol/L and 100 mol/L), and
GPBAR-A (3mol/L) significantly increased theCFP/YFP
ratio (P  .05 vs baseline), and no statistical differences
were found between TDCA and TLCA.
Next we monitored Ca2 in ileal L-cells using the sen-
sorGCaMP3, expressed specifically inL-cells in themouse
Figure 1. Bile acid–induced GLP-1 secretion. Small intestinal (A) or colonic (B) cultures were incubated for 2 hours in saline solution containing 10
mmol/L glucose (control [Con]) and the following stimuli at the concentrations indicated (mol/L): F/I, forskolin (10 mol/L) plus IBMX (10 mol/L),
TCA, TDCA, TLCA, GPBAR-A (GP-A) (3 mol/L), and GW4064 (GW) (5 mol/L). GLP-1 release is expressed as a percentage of content. The results
are the means 
 SEM of n 	 12 to 23 wells (A) and n 	 12 wells, all bile acids at 100 mol/L (B), with 3 to 4 wells originating from a single
mouse performed in parallel. Statistical differences were determined using a one-way ANOVA and a post hoc Bonferroni test on log10-transformed
data. Statistical differences from basal (*) or TDCA at 100 mol/L (†) are displayed: **/††, P  .01; ***/†††, P  .001.
Figure 2. Intracellular cAMP and Ca2 changes in L-cells. Mixed intestinal cultures were generated from the lower small intestine of mice
expressing Epac2camps (A and B) or GCaMP3 (C and H) in L-cells. Cells were perfused with stimuli as indicated in saline buffer containing 10
mmol/L glucose. A, Representative cAMP response from an L-cell stimulated with GPBAR-A (GP-A; 3 mol/L), TDCA (10 mol/L), TLCA (10 mol/
L), and forskolin (10 mol/L) plus IBMX (100 mol/L) (F/I). B, Mean fold change in the CFP/YFP ratio, representing [cAMP], for cells recorded as in
A. Error bars represent SEM; numbers of individual cells are indicated above the bars. Statistical differences from basal were determined by a one-
sample t test (*, P  .05; **, P  .01; ***, P  .001). Bile acids were applied at 10 or 100 mol/L as indicated. C–E, Representative L-cell calcium
responses measured as GCaMP3 fluorescence (Fl) to TDCA at the concentrations indicated and 30 mmol/L KCl (C), GPBAR-A (GP-A, 3 mol/L),
GW4064 (GW, 5 mol/L), or TDCA (100 mol/L) (D and E). F, Mean increase in GCaMP3 fluorescence over baseline (Fl/Fl0) for cells recorded as in
C to E. TLCA and TDCA concentrations were 10 or 100 mol/L as indicated. Cells that did not respond to any stimuli were excluded from analysis
(4 of 28). Results are means 
 SEM, and numbers of individual cells are indicated above the bars. Statistical differences from basal signal (*) were
determined via one-sample t tests and statistical differences from TDCA (†) were determined by a one-way ANOVA and post hoc Bonferroni test
on log10-transformed data (*/†, P  .05; ††, P  .01; ***, P  .001). G and H, Cells were recorded and analyzed as in C–F, but in the presence of
CoCl2 (5 mmol/L) to block voltage-gated Ca
2 channels. BBS (100 nmol/L) was used as a positive control. Two of 14 cells were excluded. ***, P 
.001 by a one-sample t test on log10-transformed data compared with basal.
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strain GLU-Cre/ROSA26-GCaMP3. TDCA at 100
mol/L triggered a rapid and reversible 1.7-fold increase
in GCaMP3 fluorescent intensity, indicative of an eleva-
tion of intracellular Ca2. This was significantly greater
than the responses observedwith 100mol/L TLCA (1.2-
fold increase,P .05). TheGPBAR1 agonist and the FXR
agonist GW4064 triggered only small changes in
GCaMP3 fluorescence (Figure 2, C–F). This pattern of
Ca2 responsiveness supports the idea thatTDCArecruits
an additional signaling pathway in L-cells, not related to
activation of GPBAR1 or FXR. The effect of TDCA was
significantly impaired in the presence of cobalt chloride
(CoCl2, 5 mmol/L), which blocks voltage-gated calcium
channels, indicating that the Ca2 rise was largely attrib-
utable to extracellular Ca2 entry (Figure 2, G and H).
We hypothesized that TDCA transport might trigger
membrane depolarization and V-gated Ca2 entry as a
consequence of electrogenic Na-coupled influx by the
ASBT, analogous to our previous findings with sodium-
dependent glucose transporter 1 (SGLT1) (16, 23). In-
deed, Asbt was detected in ileal and colonic L-cells by
qRT-PCR (Figure 3, A and B). When extracellular Na
was reduced 25-fold to 5.6 mmol/L, however, TDCA
still elicited an elevation of intracellular Ca2 in L-cells
(Figure 3, C and D). To test the role of ASBT directly, we
used a specific ASBT inhibitor (10 mol/L) in GLP-1 se-
cretion and calcium imaging experiments. The inhibitor
did not significantly impair TDCA-triggered GLP-1 re-
lease or Ca2 responses in cell cultures, suggesting that
TDCA-induced GLP-1 secretion is not directly coupled to
bile acid uptake by L-cells via ASBT (Figure 3, E–G).
Role of bile acid uptake
To assess GLP-1 secretion from intact intestinal tissue
pieces, we adapted the use of Ussing chambers, in which
epithelial integrity is maintained and test agents can be
Figure 3. The role of ASBT in bile acid–induced GLP-1 release and intracellular Ca2 changes. Expression of Asbt was determined in
homogenized intestine segments (A) and FACS-isolated L-cell populations (B). Expression of Asbt (Slc10a2) in control cells () and L-cells (f) was
determined relative to that of -actin by qRT-PCR. Up SI, upper 10 cm of the small intestine; low SI, lower 12 cm of the small intestine; LI, large
intestine. Mean CT and upper SEM were calculated from 3 independent experiments and are presented as 2
CT. Statistical tests were assessed on
nontransformed data using a one-way ANOVA and post hoc Bonferroni test (A) or two-tailed t tests (B) (*, P  .05; **, P  .01). C–F, Mixed lower
small intestinal cultures of mice expressing GCaMP3 in L-cells were perfused with standard saline containing 10 mmol/L glucose and additions as
indicated. C, Representative trace depicting GCaMP3 fluorescence (Fl) in response to TDCA (100 mol/L) applied in standard and low (5.6 mmol/L)
Na saline and 30 mmol/L KCl. D, Mean increase in GCaMP3 fluorescence over baseline (Fl/Fl0) for cells recorded as in C. Cells that did not
respond to any stimuli (all responses 1.1-fold) were excluded (2 of 14). Results are means 
 SEM (n 	 12). Statistical significance from basal was
determined on log10-transformed data via a one-sample t test (**, P  .01). E, Representative trace depicting a calcium response to TDCA (10
mol/L) with and without the ASBT inhibitor (ASBT-I; 10 mol/L). F, Mean 
 SEM data are recorded as in E (n 	 4). Statistical analysis was
performed as in D (***, P  .001 from basal). G, Lower small intestinal cultures were incubated for 2 hours in saline solution containing 10 mmol/
L glucose and stimuli as indicated. Test agents were TDCA (100 mymol/L), ASBT-I (10 mol/L), and 10 mol/L forskolin plus 10 mol/L IBMX (F/I).
GLP-1 release is expressed as a percentage of content. Results are means 
 SEM of n 	 12 wells, with 4 wells originating from a single mouse
performed in parallel. Statistical differences were determined using a one-way ANOVA and post hoc Bonferroni test on log10-transformed data
(**, P  .01; ***, P  .001, compared with basal).
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applied independently to the luminal or basolateral com-
partments. In validation experiments on sheets of terminal
ileum, bilateral addition of forskolin plus IBMX elicited a
robustGLP-1 secretory response into the basolateral com-
partment of the chambers (Figure 4A).
When TDCA (100mol/L) or TLCA (100mol/L)was
applied to either the apical or basolateral compartment,
GLP-1 release was elevated comparedwith that for controls
(Figure 4A). For both bile acids, basolaterally stimulated
GLP-1 releasewas greater than that when theywere applied
Figure 5. Bile acid–induced GLP-1 secretion from GPBAR-knockout mice. GLP-1 secretion was measured from small intestinal cultures or tissue
sections from wild-type () and GPBAR-knockout (f) mice. A, Cultures were incubated for 2 hours in saline solution containing 10 mmol/L
glucose (control [Con]) and the following stimuli at the concentrations indicated (mol/L): F/I, forskolin (10 mol/L) plus IBMX (10 mol/L), TCA,
TDCA, TLCA, and GPBAR-A (GP-A) (3 mol/L). GLP-1 release is expressed as a percentage of content. Results are means 
 SEM of n 	 9 wells,
with 3 wells originating from a single mouse performed in parallel. B, Concentration change in GLP-1 in the basolateral compartment of Ussing
chambers was assessed after 1 hour without treatment or with treatment with TDCA (100 mol/L), TLCA (100 mol/L), applied to the basolateral
compartment, or forskolin (10 mol/L) plus IBMX (100 mol/L) (F/I), applied bilaterally. Results are normalized per 1 cm2 tissue area. Data are
means 
 SEM (n 	 3–4). Statistical differences were determined using a two-way ANOVA and post hoc Bonferroni test on log10-transformed
data. Statistical elevations from control (*) or differences between wild-type and knockout (†) mice are displayed: */†, P  .05; **, P  .01;
***/†††, P  .001.
Figure 4. GLP-1 secretion from murine ileal epithelial tissues mounted in Ussing chambers and from perfused rat intestine. A, Concentration
change in GLP-1 in the basolateral compartment of Ussing chambers was assessed after 1 hour without treatment (left-hand column) or with
treatment with TDCA (100 mol/L), TLCA (100 mol/L), GPBAR-A (GP-A; 3 mol/L), or forskolin (10 mol/L) plus IBMX (100 mol/L) (F/I), applied
to the apical (Ap), basolateral (Ba), or both compartments (bilaterally [Bi]) as indicated. At 10 minutes before application of TDCA, some tissues
were pretreated bilaterally with 10 mol/L ASBT inhibitor (ASBT-I). Results are normalized per 1 cm2 tissue area. Means
 SEM and numbers of tissue
sheets are indicated. Statistical differences were determined on log10-transformed data using a one-way ANOVA and post hoc Bonferroni test either from
basal (*) or between conditions as indicated (†) (†, P .05; **/††, P .01; ***, P .001). B–D, TDCA-stimulated GLP-1 secretion from perfused rat
intestine. B, TDCA (100 mol/L) was applied to either the luminal (Lum) or vascular (Vasc) side. C, TDCA (1 mmol/L) was applied to the luminal side. BBS
(10 nmol/L, vascular) was included at the end of all experiments as a positive control. Meas
 SEM GLP-1 responses from n	 6 to 7 perfused rat
intestines (B and C) and time-averaged GLP-1 levels at baseline () and during TDCA addition (u, 100 mol/L/f, 1 mmol/L) (D) for experiments
performed as in B and C are shown. Statistical differences from basal (*) were determined by a one-way ANOVA and post hoc Bonferroni test
(***, P .001).
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apically, although this difference reached statistical signifi-
cance only for TDCA (Figure 4A, P .05). Bilateral appli-
cation of theASBT inhibitor largely abolished secretion trig-
gered by subsequent apical TDCA but did not impair the
responses to basolateral TDCA (Figure 4A). This result sug-
gested that TDCA stimulated GLP-1 secretion after its
ASBT-dependent transport fromtheapical to thebasolateral
compartment but did not require ASBT-dependent uptake
by L-cells themselves. Application of GPBAR-A from the
basolateral but not the apical direction also increasedGLP-1
release(Figure4A),suggestingaroleforbasolaterally located
GPBAR1 on L-cells.
To validate the Ussing chambermethod, we performed
comparative experiments in the perfused rat intestinal
model. In support of the findings from the Ussing cham-
bers, applicationof 100mol/LTDCAvia the vasculature
robustly and reversibly increased GLP-1 release. Luminal
application of the same TDCA concentration was largely
ineffective (Figure 4, B and D), whereas 1 mmol/L TDCA
stimulated GLP-1 secretion (1 mmol/L TDCA was not
tolerated when applied via the vasculature, Figure 4C).
Role of GPBAR1
To assess the extent to which GPBAR1 is responsible
for bile acid–stimulated GLP-1 release from L-cells, we
measured GLP-1 secretion from GPBAR1-knockout
mouse intestinal cultures and Ussing chamber-mounted
tissue sections (Figure 5). TDCA, TCA, andTLCAdid not
significantly increaseGLP-1 secretionabovebasal levels in
primary intestinal cultures generated from GPBAR1-
knockout mice (Figure 5A). In cultures from matched
wild-type controls, GLP-1 levels were increased by bile
acids and the GPBAR agonist (GPABAR-A) and were sig-
nificantly greater than in cultures from GPBAR1-knock-
out animals for these agents (P  .001; Figure 5A). Sim-
ilarly, TDCA and TLCA did not significantly stimulate
GLP-1 secretion from GPBAR-knockout intestinal tissue
sections mounted in Ussing chambers when applied to the
basolateral compartment, whereas both bile acids trig-
gered robust GLP-1 secretory responses in tissues from
matched wild-type mice (P  .05; Figure 5B). No differ-
ences were observed for forskolin/IBMX-stimulated
GLP-1 secretion betweenwild-type and knockout derived
tissues in primary cultures or Ussing chambers (Figure 5).
These data indicate that GPBAR1 is essential for mediat-
ing bile acid–stimulated GLP-1 release from L-cells.
Discussion
In this study, we investigated the effects of bile acids on
L-cell function using a variety of techniques ranging from
single cell imaging tomeasurements ofGLP-1 release from
the perfused intact gut. We also optimized and evaluated
small-volume Ussing chambers as a technique for directly
measuring gut hormone release from intact sheets of in-
testine. Our system generated GLP-1 concentrations, fall-
ing reliably within the working range of available immu-
noassays, even under basal (unstimulated) conditions, in
contrast to previous reports using a similar approach (27).
The method also differs from previous Ussing chamber
studies that used changes in the short circuit current as a
surrogate for hormonal release (28) and evaluation of the
directionality of action of GPR119 agonists (29). Overall,
our results indicate that bile acids trigger elevation of
cAMP and Ca2 in L-cells, but that the predominant link
between luminal bile acids and GLP-1 release is probably
mediated by GPBAR1 located on the basolateral L-cell
membrane.
Consistentwith theknowncouplingofGPBAR1toGs
proteins andactivationof adenylate cyclase (26), bile acids
increased cAMP concentrations in primary cultured L-
cells. In addition, however, we found that TDCA substan-
tially elevated L-cell intracellular Ca2. This latter effect
was not mimicked by ligands of GPBAR1 or FXR and
involved Ca2 entry through plasma membrane calcium
channels, suggesting that it might occur downstream of
membrane depolarization. We hypothesized that this
Ca2 signal might be linked to bile acid uptake by ASBT,
which cotransports at least 2 Na ions for each bile acid
molecule (30). If electrogenic ion transport occurs at a
sufficient rate, it can lead to membrane depolarization, as
reported previously for the SGLT1 (31). A highly selective
ASBT inhibitor did not, however, impair TDCA-triggered
GLP-1 secretion from primary cultures. Surprisingly, the
ASBT inhibitor induced a small but significant reduction
in basal GLP-1 release, suggesting that ASBT has intrinsic
activity in L-cells even in the absence of added bile acids.
Consistent with this idea, when ASBT was expressed in
Xenopus oocytes, a bile-acid independent background
current was reported (32). However, the lack of effect of
the ASBT inhibitor on TDCA-triggered Ca2 signals in
L-cells indicated that an alternative mechanism is likely to
underlie these responses. Bile acids have been reported to
increase Ca2 in a number of cell types, via mechanisms
not yet identified at the molecular level (33). We searched
our microarray transcriptomic database (34) for previ-
ously reported bile acid–sensitive proteins expressed in
L-cells, but no convincing candidates were identified.
ASIC5 has been reported to behave as a bile acid-activated
amiloride-sensitive ion channel in some species (35) and
was detected by microarray in L-cells, but seems not to
underlie theCa2 responses inL-cells, as amiloride didnot
prevent the Ca2 signal triggered by TDCA (data not
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shown). Our data do not therefore allow us to draw con-
clusions about the molecular mechanisms underlying
TDCA-triggered Ca2 responses in L-cells. Although fur-
ther calcium imaging experiments on GPBAR1-knockout
tissues could address the requirement of GPBAR1 for this
response, it appears that a putativeGPBAR1-independent
rise in cytosolic Ca2would be insufficient to stimulate a
secretory response.
Our data from the perfused intestine and Ussing cham-
bers suggest that the predominant effect of bile acids on
GLP-1 release in intact tissue is triggered by GPBAR1 ac-
tivation on the basolateral L-cell membrane. Findings in
support of this idea are that basolaterally applied TDCA
was more effective than apical TDCA in the perfused in-
testine and Ussing chamber system, that the ASBT inhib-
itor blocked apical TDCA-triggered but not basolateral
TDCA-triggered GLP-1 release in Ussing chambers, that
GPBAR agonist was effective only when applied to the
basolateral compartment of Ussing chambers, and that
bile acids did not stimulate GLP-1 secretion from GP-
BAR1-knockout mouse tissue. The location of GPBAR1
on L-cells has previously been difficult to pinpoint by im-
munomicroscopy, but a previous study also found that a
nonabsorbable GPBAR1 agonist only triggeredGLP-1 re-
lease when administered systemically, suggesting that the
receptor is accessible from the basolateral but not the api-
cal intestinal compartment (12). This is a critical issue for
the field of therapeutic GPBAR1 agonist development.
Previous reports that GPBAR1 agonists exhibited gall-
bladder toxicity in animal models (13) led to the sugges-
tion that nonabsorbableGPBAR1 ligands or agonistswith
low systemic exposure might be required to target L-cells
without triggering systemic side effects. Our data, how-
ever, suggest that luminally restricted agents would not
elicit a strong GLP-1 secretory response in vivo.
Although bile acids are widely believed to play impor-
tant roles in metabolism and to mediate beneficial effects
after gastric bypass surgery (7, 10), published data on the
effects of bile acid sequestrants and ASBT inhibitors on
GLP-1 secretion have been inconclusive. The bile acid se-
questrant, colesevelam, for example, acutely increased
postprandial GLP-1 levels in humans, but the effect was
not sustained at 4 weeks (36). Two weeks of treatment
with an ASBT inhibitor, in contrast, resulted in persis-
tently enhancedGLP-1 levels in rats (37).Our finding that
bile acids predominantly act from the basolateral com-
partment offers some clarity to this field.On the one hand,
treatment with sequestrants or ASBT inhibitors increases
the delivery of nonabsorbed bile acids to the large intes-
tine, with its dense L-cell population. In the colon, bile
acids are modified by microbiota, and the resultant un-
conjugated secondary bile acids are absorbed passively
(38). Increased colonic bile acid delivery could therefore
result in increased bile acid concentrations in the basolat-
eral compartment surrounding colonic L-cells and GP-
BAR1-dependent GLP-1 release. On the other hand, the
aim of long-term administration of bile acid sequestrants
andASBT inhibitors is to deplete the plasma bile acid pool
and tends to counteract some of this effect.
In summary, we find that bile acids trigger a variety of
signaling pathways in L-cells, but it seems that GLP-1 re-
lease is largely determined by GPBAR1 activation. The
location of functional GPBAR1 appears to be mostly ba-
solateral on L-cells, requiring an initial step involving ab-
sorption across the intestinal epithelium before bile acids
or GPBAR1 agonists can trigger GLP-1 secretion. This
requirement for systemic availability of GPBAR1 ligands
will make it difficult to harness this receptor therapeuti-
cally because of the reported gallbladder toxicity of sys-
temically available agonists. Increasing delivery of bile ac-
ids to thedistal gut bybariatric surgical procedures, resins,
or ASBT inhibitors might, however, offer effective strat-
egies to elevate concentrations of GPBAR1 ligands in the
local vicinity of colonic L-cells.
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